Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INCALXO · Entity 6040 | PRESIDENT & CSO | February 19, 2025 | February 21, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALX ONCOLOGY HOLDINGS INC
Report date February 19, 2025 · Filed February 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 579,388 |
Reported balance
After 2025-02-19 transaction · row 1
1 source rowRow 1 · 2025-02-19 · Sale · Disposed 1,326 · Balance 579,388 F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were sold to satisfy the reporting person's tax obligations in connection with the vesting of restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.15 to $1.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 21, 2021 Filed Jun 22, 2021 16:26 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 10,353 | $58.92 | $609,975.98 |
DisclosureSEC source: 0001209191-21-042395 · doc4.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511,246 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.58 to $59.22, inclusive. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 16:26 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 6,347 | $58.06 | $368,504.28 |
DisclosureSEC source: 0001209191-21-042395 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 521,599 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.56 to $58.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| May 19, 2021 Filed May 20, 2021 19:52 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 979 | $56.71 | $55,514.59 |
DisclosureSEC source: 0001209191-21-034662 · doc4.xml · nonDerivative · entry 3 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 527,946 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F4 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.59 to $56.83, inclusive. Read SEC document |
| May 19, 2021 Filed May 20, 2021 19:52 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 15,221 | $55.69 | $847,659.01 |
DisclosureSEC source: 0001209191-21-034662 · doc4.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528,925 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F3 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.50 to $56.35, inclusive. Read SEC document |
| May 19, 2021 Filed May 20, 2021 19:52 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 500 | $54.20 | $27,102.40 |
DisclosureSEC source: 0001209191-21-034662 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,146 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F2 · shares: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.53 to $54.52, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (4) to this Form 4. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:14 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 837 | $60.48 | $50,617.83 |
DisclosureSEC source: 0000899243-21-016591 · doc4.xml · nonDerivative · entry 5 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 544,646 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.27 to $61.01, inclusive. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:14 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 663 | $59.52 | $39,460.04 |
DisclosureSEC source: 0000899243-21-016591 · doc4.xml · nonDerivative · entry 4 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 545,483 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.21 to $60.20, inclusive. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:14 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,914 | $58.36 | $170,054.05 |
DisclosureSEC source: 0000899243-21-016591 · doc4.xml · nonDerivative · entry 3 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 546,146 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.125 to $58.90, inclusive. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:14 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 6,956 | $57.73 | $401,568.49 |
DisclosureSEC source: 0000899243-21-016591 · doc4.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 549,060 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.11 to $58.09, inclusive. Read SEC document |
| April 19, 2021 Filed Apr 21, 2021 16:14 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 5,330 | $56.42 | $300,732.99 |
DisclosureSEC source: 0000899243-21-016591 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 556,016 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.10 to $57.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 21:39 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000899243-21-013739 · doc4.xml · derivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,179 Underlying: Common Stock · 10,000 shares Expires 2027-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on May 1, 2017. Read SEC document |
| March 25, 2021 Filed Mar 26, 2021 21:39 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0000899243-21-013739 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 16,700 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0000899243-21-013283 · doc4.xml · derivative · entry 9 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,019 Underlying: Common Stock · 16,700 shares Expires 2029-09-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The option is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on June 16, 2019. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 600 | $70.12 | $42,074.58 |
DisclosureSEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 8 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,346 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.20, inclusive. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 9,200 | $69.77 | $641,857.32 |
DisclosureSEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 7 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,946 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.97 to $69.95, inclusive. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 2,700 | $68.27 | $184,329.00 |
DisclosureSEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 6 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,146 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.81 to $68.80, inclusive. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,500 | $67.18 | $100,773.45 |
DisclosureSEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 5 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 563,846 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.81 to $67.79, inclusive. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 600 | $66.33 | $39,795.00 |
DisclosureSEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 4 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,346 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.80 to $66.69, inclusive. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 900 | $64.98 | $58,486.14 |
DisclosureSEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 3 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 565,946 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.64 to $65.25, inclusive. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | SaleCommon Stock | 1,200 | $63.79 | $76,545.00 |
DisclosureSEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 566,846 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 28, 2021. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.33 to $64.25, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (8) to this Form 4. Read SEC document |
| March 22, 2021 Filed Mar 24, 2021 16:05 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionCommon Stock | 16,700 | $1.91 | $31,897.00 |
DisclosureSEC source: 0000899243-21-013283 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 06:01 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0000899243-21-003565 · doc4.xml · derivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,179 Underlying: Common Stock · 10,000 shares Expires 2027-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on May 1, 2017. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 06:01 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | Exercise / conversionCommon Stock | 10,000 | $0.99 | $9,900.00 |
DisclosureSEC source: 0000899243-21-003565 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 551,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 19:54 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries C Convertible Preferred Stock · Derivative | 5,264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019904 · doc4.xml · derivative · entry 4 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,264 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.exercise_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · derivative.expiration_date: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 19:54 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries A Convertible Preferred Stock · Derivative | 1,803 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019904 · doc4.xml · derivative · entry 3 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,803 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.exercise_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · derivative.expiration_date: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 19:54 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionSeries A Convertible Preferred Stock · Derivative | 20,225 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019904 · doc4.xml · derivative · entry 2 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,225 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. Read SEC document |
| July 21, 2020 Filed Jul 21, 2020 19:54 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | ConversionCommon Stock | 27,292 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-019904 · doc4.xml · nonDerivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,346 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2 · price: Each share of Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3 · price: Each share of Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F4 · balance_after: Includes 4,982 shares of Common Stock issued as payment of accrued dividends upon conversion of the preferred stock on July 21, 2020. Read SEC document |
| July 16, 2020 Filed Jul 17, 2020 19:00 UTC | ALX ONCOLOGY HOLDINGS INC ALXO · Entity 6040 | GrantEmployee Stock Option (right to buy) · Derivative | 272,771 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-019572 · doc4.xml · derivative · entry 1 Pons Jaume · CIK 0001816977 · Director · President &CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,771 Underlying: Common Stock · 272,771 shares Expires 2030-07-16 F1 · derivative.exercise_date: Shares subject to the option vest in 48 equal monthly installments beginning on August 16, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.